Ditch Medicare Advantage and replace it with Medicare Part F; turning to the real mental health experts; and more

Opinion and perspective essays curated by First Opinion editor Patrick Skerrett ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by        During the midpoint of November, First Opinion authors called for ditching Medicare Advantage and replacing it with Medicare "Part F;" advocated for seeing people with mental illness as experts in mental health; and more. Podcast fans: Check out the first ever recording of the First Opinion Podcast in front of a live audience, with physician/storyteller Jay Baruch. Replace the failure of Medicare Advantage with 'Medicare Part F' By Steve Cohen Adobe Medicare Advantage began life as a brilliant idea, but has gone off the rails. A new approach, "Part F," could revitalize the program. Read More Unseen mental health experts: people with mental illness By Ken Duckworth Adobe Building a stronger, more accessible mental health system should include the valuable perspectives of people with mental illness. Read More STAT+: The conundrum of biopharma investing: low rewards and high risks — but a big social benefit By Anup Srivastava and Rong Zhao and Ge Bai Adobe Risk-reward parity says expected returns on investments should be commensurate with the risks. That's not the case for biopharma investing. Read More Sponsored Insight by Phlow The true costs of foreign API and the domestic CDMO solution More than 80% of the active pharmaceutical ingredients used to manufacture today's vital medications are produced abroad. But what is the true cost of relinquishing control of the supply of our Nation's essential medicines to foreign sources? By collaborating with a variety of pharmaceutical and biotech companies, Phlow provides expert consultation and differentiated R&D services, through their SMART-CDMO, in an effort to re-shore the manufacturing of essential and innovative medicines for good. Learn more. Listen: The 'First Opinion Podcast' live from Boston: Jay Baruch returns By Patrick Skerrett Emergency physician Jay Baruch penned a letter to his boss spelling out his intention to leave medicine behind. The aftermath surprised him. Read More STAT+: Removing barriers to biosimilar adoption in the United States By Thomas Newcomer Adobe Misperceptions of inferiority and the intricacies of the domestic market access are limiting biosimilar adoption in the U.S. Read More We know what it's like to live in fear of polio. We also know how to stop it By Rose Gana Fomban Leke and Zulfiqar Bhutta Farooq Naeem / Getty Polio, like every virus, knows no borders. All countries need to pitch in and apply lessons learned in countries dealing with it. Read More Better access to amyloid-PET scans won't reduce racial inequities in Alzheimer's disease By Poul Høilund-Carlsen and Abass Alavi and Jorge R. Barrio FRED TANNEAU/AFP via Getty Images Opening access to PET-amyloid scans will result in more people misdiagnosed with Alzheimer's disease and given an unproven treatment for it. Read More Sunday, November 20, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser